Supernus, Inc. SUPN
SUPN among the 162 companies we cover
Where it stands · the better end on the right. The band holds the middle half; the line is the median.
SUPN and 9 peers, year by year
The 9 Health care companies closest to SUPN in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.
Choose the peers
| Company | Year | Revenue | Sales growth | Gross margin | Operating margin | Net margin | FCF margin | Return on equity | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|
| SUPN Supernus, Inc. | FY2025 | $719.0M | +8.6% | - | −8.7% | −5.4% | 6.4% | −3.6% | - |
| AXSM Axsome Therapeutics, Inc. | FY2025 | $638.5M | +65.5% | - | −26.1% | −28.7% | −14.7% | n/m | 2.13 |
| IRTC iRhythm Holdings, Inc. | FY2025 | $747.1M | +26.2% | 70.6% | −7.7% | −6.0% | 4.6% | −29.2% | - |
| INSP Inspire Medical Systems, Inc. | FY2025 | $912.0M | +13.6% | 85.4% | 5.6% | 15.9% | 8.6% | 18.6% | - |
| TGTX TG Therapeutics, Inc. | FY2025 | $616.3M | +87.3% | - | 20.0% | 72.6% | −4.1% | 69.0% | 0.38 |
| RGEN Repligen Corp | FY2025 | $738.3M | +16.4% | - | 7.5% | 6.6% | 12.7% | 2.3% | 0.26 |
| WRBY Warby Parker Inc. | FY2025 | $871.9M | +13.0% | 54.0% | −0.6% | 0.2% | 5.0% | 0.4% | - |
| BBIO BridgeBio Pharma, Inc. | FY2025 | $502.1M | +126% | - | −104.2% | −144.4% | −89.0% | n/m | n/m |
| IONS Ionis Pharmaceuticals Inc | FY2025 | $943.7M | +33.8% | - | −40.4% | −40.4% | −33.9% | −78.0% | 3.71 |
| BCRX Biocryst Pharmaceuticals Inc | FY2025 | $874.8M | +94.1% | - | 39.0% | 30.2% | 39.4% | n/m | n/m |
Each company, year by year
Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2016 to FY2025 · 10-K XBRL
Who rewrote the most
Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before
Revenue, FY2016 to FY2025
Revenue as reported in the 10-K.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SUPN Dec | $215.0M | $302.2M | $408.9M | $392.8M | $520.4M | $579.8M | $667.2M | $607.5M | $661.8M | $719.0M |
| AXSM Dec | - | - | - | - | $0 | $0 | $50.0M | $270.6M | $385.7M | $638.5M |
| IRTC Dec | $64.1M | $99.1M | $147.3M | $214.6M | $265.2M | $322.8M | $410.9M | $492.7M | $591.8M | $747.1M |
| INSP Dec | $16.4M | $28.6M | $50.6M | $82.0M | $115.4M | $233.4M | $407.9M | $624.8M | $802.8M | $912.0M |
| TGTX Dec | $152K | $152K | $152K | $152K | $152K | $6.7M | $2.8M | $233.7M | $329.0M | $616.3M |
| RGEN Dec | $104.5M | $141.2M | $194.0M | $270.2M | $366.3M | $670.5M | $801.5M | $632.4M | $634.4M | $738.3M |
| WRBY Dec | - | - | - | $370.5M | $393.7M | $540.8M | $598.1M | $669.8M | $771.3M | $871.9M |
| BBIO Dec | - | - | - | $40.6M | $8.2M | $69.7M | $77.6M | $9.3M | $221.9M | $502.1M |
| IONS Dec | $372.8M | $514.2M | $599.7M | $1.1B | $729.3M | $810.5M | $587.4M | $787.6M | $705.1M | $943.7M |
| BCRX Dec | $26.4M | $25.2M | $20.7M | $48.8M | $17.8M | $157.2M | $270.8M | $331.4M | $450.7M | $874.8M |
| Peer median | $45.2M | $63.8M | $98.9M | $148.3M | $115.4M | $233.4M | $407.9M | $492.7M | $591.8M | $747.1M |
Sales growth, FY2016 to FY2025
Revenue against the fiscal year before.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SUPN Dec | +45.8% | +40.6% | +35.3% | −3.9% | +32.5% | +11.4% | +15.1% | −8.9% | +8.9% | +8.6% |
| AXSM Dec | - | - | - | - | - | - | - | +441% | +42.5% | +65.5% |
| IRTC Dec | +77.3% | +53.7% | +48.6% | +45.7% | +23.6% | +21.7% | +27.3% | +19.9% | +20.1% | +26.2% |
| INSP Dec | - | +73.9% | +77.1% | +62.2% | +40.6% | +102% | +74.7% | +53.2% | +28.5% | +13.6% |
| TGTX Dec | - | 0.0% | 0.0% | 0.0% | 0.0% | n/m | −58.4% | n/m | +40.8% | +87.3% |
| RGEN Dec | +25.1% | +35.1% | +37.4% | +39.3% | +35.5% | +83.1% | +19.5% | −21.1% | +0.3% | +16.4% |
| WRBY Dec | - | - | - | - | +6.3% | +37.4% | +10.6% | +12.0% | +15.2% | +13.0% |
| BBIO Dec | - | - | - | - | −79.7% | +745% | +11.4% | −88.0% | n/m | +126% |
| IONS Dec | +22.2% | +37.9% | +16.6% | +87.2% | −35.0% | +11.1% | −27.5% | +34.1% | −10.5% | +33.8% |
| BCRX Dec | −45.4% | −4.4% | −18.0% | +136% | −63.5% | +782% | +72.3% | +22.4% | +36.0% | +94.1% |
| Peer median | +23.7% | +36.5% | +27.0% | +53.9% | +3.1% | +83.1% | +15.5% | +21.1% | +24.3% | +33.8% |
Gross margin, FY2016 to FY2025
Gross profit / revenue.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SUPN Dec | - | - | - | - | - | - | - | - | - | - |
| AXSM Dec | - | - | - | - | - | - | - | - | - | - |
| IRTC Dec | 67.4% | 71.5% | 73.7% | 75.5% | 73.5% | 66.2% | 68.5% | 67.3% | 68.9% | 70.6% |
| INSP Dec | 76.2% | 78.9% | 80.1% | 83.4% | 84.7% | 85.7% | 83.8% | 84.5% | 84.7% | 85.4% |
| TGTX Dec | - | - | - | - | - | - | - | - | - | - |
| RGEN Dec | - | - | - | - | - | - | - | - | - | - |
| WRBY Dec | - | - | - | 60.2% | 58.9% | 58.8% | 57.0% | 54.5% | 55.3% | 54.0% |
| BBIO Dec | - | - | - | - | - | - | - | - | - | - |
| IONS Dec | - | - | - | - | - | - | - | - | - | - |
| BCRX Dec | - | - | - | - | - | - | - | - | - | - |
| Peer median | - | - | - | 75.5% | 73.5% | 66.2% | 68.5% | 67.3% | 68.9% | 70.6% |
Operating margin, FY2016 to FY2025
Operating income / revenue.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SUPN Dec | 25.2% | 32.9% | 35.3% | 37.8% | 33.4% | 14.8% | 6.9% | −0.9% | 12.3% | −8.7% |
| AXSM Dec | - | - | - | - | - | - | −359.3% | −85.7% | −72.7% | −26.1% |
| IRTC Dec | −24.3% | −27.8% | −31.0% | −25.5% | −16.5% | −31.0% | −27.7% | −25.4% | −19.5% | −7.7% |
| INSP Dec | −105.0% | −56.0% | −40.3% | −42.5% | −48.7% | −17.1% | −11.7% | −6.4% | 4.5% | 5.6% |
| TGTX Dec | n/m | n/m | n/m | n/m | n/m | n/m | n/m | 8.8% | 12.7% | 20.0% |
| RGEN Dec | 15.3% | 9.9% | 13.4% | 13.4% | 19.1% | 24.9% | 28.0% | 7.5% | −5.5% | 7.5% |
| WRBY Dec | - | - | - | −0.4% | −14.1% | −26.6% | −18.6% | −10.7% | −3.9% | −0.6% |
| BBIO Dec | - | - | - | −656.4% | n/m | −827.1% | −659.6% | n/m | −267.2% | −104.2% |
| IONS Dec | −5.4% | 6.0% | −10.2% | 32.6% | −23.6% | −3.7% | −69.8% | −44.9% | −67.4% | −40.4% |
| BCRX Dec | −184.4% | −227.9% | −456.2% | −203.7% | −981.1% | −113.1% | −54.8% | −31.3% | −0.6% | 39.0% |
| Peer median | −24.3% | −27.8% | −31.0% | −25.5% | −20.0% | −26.6% | −41.2% | −18.1% | −5.5% | −0.6% |
Net margin, FY2016 to FY2025
Net income / revenue.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SUPN Dec | 42.4% | 19.0% | 27.1% | 28.8% | 24.4% | 9.2% | 9.1% | 0.2% | 11.2% | −5.4% |
| AXSM Dec | - | - | - | - | - | - | −374.0% | −88.4% | −74.5% | −28.7% |
| IRTC Dec | −32.6% | −30.0% | −34.2% | −25.4% | −16.5% | −31.4% | −28.3% | −25.0% | −19.1% | −6.0% |
| INSP Dec | −112.8% | −61.3% | −43.1% | −40.5% | −49.6% | −18.0% | −11.0% | −3.4% | 6.7% | 15.9% |
| TGTX Dec | n/m | n/m | n/m | n/m | n/m | n/m | n/m | 5.4% | 7.1% | 72.6% |
| RGEN Dec | 11.2% | 20.1% | 8.6% | 7.9% | 16.4% | 19.1% | 23.2% | 5.6% | −4.0% | 6.6% |
| WRBY Dec | - | - | - | 0.0% | −14.2% | −26.7% | −18.5% | −9.4% | −2.6% | 0.2% |
| BBIO Dec | - | - | - | −642.5% | n/m | −806.9% | −619.7% | n/m | −241.4% | −144.4% |
| IONS Dec | −16.2% | 0.1% | 45.6% | 24.8% | −60.9% | −3.5% | −45.9% | −46.5% | −64.4% | −40.4% |
| BCRX Dec | −209.3% | −261.2% | −490.3% | −223.0% | n/m | −117.1% | −91.2% | −68.4% | −19.7% | 30.2% |
| Peer median | −32.6% | −30.0% | −34.2% | −25.4% | −16.5% | −26.7% | −37.1% | −17.2% | −19.1% | 0.2% |
Free cash flow, FY2016 to FY2025
Cash from operations minus capital spending.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SUPN Dec | $65.2M | $112.6M | $128.1M | $140.4M | $134.9M | - | $116.4M | $110.5M | $171.2M | $46.0M |
| AXSM Dec | −$21.4M | −$26.5M | −$30.1M | −$46.4M | −$78.5M | −$108.5M | −$117.2M | −$145.7M | −$128.7M | −$93.9M |
| IRTC Dec | −$19.4M | −$18.5M | −$34.3M | −$42.3M | −$27.3M | −$65.8M | −$52.8M | −$90.5M | −$30.6M | $34.5M |
| INSP Dec | −$18.3M | −$16.2M | −$18.9M | −$35.6M | −$55.5M | −$24.8M | $2.5M | $1.0M | $91.1M | $78.5M |
| TGTX Dec | −$61.9M | −$93.8M | −$129.0M | −$132.9M | −$214.9M | −$296.0M | −$176.2M | −$31.4M | −$40.6M | −$25.0M |
| RGEN Dec | $3.2M | $12.0M | $22.1M | $48.7M | $40.2M | $51.9M | $87.2M | $77.7M | $149.7M | $93.9M |
| WRBY Dec | - | - | - | −$11.2M | $12.7M | −$80.5M | −$49.8M | $7.3M | $34.7M | $43.7M |
| BBIO Dec | - | −$41.0M | −$138.8M | −$256.2M | −$407.2M | −$511.2M | −$424.3M | −$529.0M | −$521.7M | −$447.0M |
| IONS Dec | −$119.2M | $139.4M | $589.3M | $314.7M | $772K | $18.8M | −$290.1M | −$331.3M | −$546.2M | −$320.0M |
| BCRX Dec | −$58.7M | −$41.5M | −$92.9M | −$89.9M | −$135.6M | −$144.5M | −$163.2M | −$97.3M | −$53.1M | $344.9M |
| Peer median | −$21.4M | −$22.5M | −$32.2M | −$42.3M | −$55.5M | −$80.5M | −$117.2M | −$90.5M | −$40.6M | $34.5M |
FCF margin, FY2016 to FY2025
Free cash flow / revenue.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SUPN Dec | 30.3% | 37.3% | 31.3% | 35.7% | 25.9% | - | 17.4% | 18.2% | 25.9% | 6.4% |
| AXSM Dec | - | - | - | - | - | - | −234.3% | −53.8% | −33.4% | −14.7% |
| IRTC Dec | −30.3% | −18.6% | −23.3% | −19.7% | −10.3% | −20.4% | −12.9% | −18.4% | −5.2% | 4.6% |
| INSP Dec | −111.1% | −56.7% | −37.4% | −43.4% | −48.1% | −10.6% | 0.6% | 0.2% | 11.4% | 8.6% |
| TGTX Dec | n/m | n/m | n/m | n/m | n/m | n/m | n/m | −13.4% | −12.3% | −4.1% |
| RGEN Dec | 3.1% | 8.5% | 11.4% | 18.0% | 11.0% | 7.7% | 10.9% | 12.3% | 23.6% | 12.7% |
| WRBY Dec | - | - | - | −3.0% | 3.2% | −14.9% | −8.3% | 1.1% | 4.5% | 5.0% |
| BBIO Dec | - | - | - | −631.7% | n/m | −733.2% | −546.5% | n/m | −235.1% | −89.0% |
| IONS Dec | −32.0% | 27.1% | 98.3% | 28.0% | 0.1% | 2.3% | −49.4% | −42.1% | −77.5% | −33.9% |
| BCRX Dec | −222.8% | −164.7% | −450.0% | −184.1% | −761.4% | −92.0% | −60.3% | −29.4% | −11.8% | 39.4% |
| Peer median | −32.0% | −18.6% | −23.3% | −19.7% | −5.1% | −14.9% | −31.1% | −15.9% | −11.8% | 4.6% |
Return on equity, FY2016 to FY2025
Net income / shareholders' equity at the year end.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SUPN Dec | 47.6% | 21.4% | 24.5% | 19.0% | 17.0% | 6.5% | 6.9% | 0.1% | 7.1% | −3.6% |
| AXSM Dec | −126.1% | −173.1% | n/m | −38.2% | −90.4% | n/m | −170.8% | −125.3% | n/m | n/m |
| IRTC Dec | −22.5% | −37.5% | −96.6% | −40.3% | −12.8% | −36.3% | −48.4% | −58.7% | −124.6% | −29.2% |
| INSP Dec | n/m | n/m | −13.3% | −23.8% | −24.9% | −18.4% | −9.0% | −3.7% | 7.8% | 18.6% |
| TGTX Dec | n/m | −176.8% | n/m | n/m | −53.8% | −146.8% | n/m | 7.9% | 10.5% | 69.0% |
| RGEN Dec | 6.9% | 4.8% | 2.7% | 2.0% | 3.9% | 7.3% | 9.7% | 1.8% | −1.3% | 2.3% |
| WRBY Dec | - | - | - | n/m | n/m | −50.4% | −38.5% | −20.9% | −6.0% | 0.4% |
| BBIO Dec | - | −35.6% | −41.5% | −63.8% | n/m | n/m | n/m | n/m | n/m | n/m |
| IONS Dec | −60.7% | 0.1% | 26.1% | 18.9% | −59.8% | −3.7% | −47.1% | −94.7% | −77.1% | −78.0% |
| BCRX Dec | n/m | −78.5% | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m |
| Peer median | −41.6% | −37.5% | −13.3% | −31.0% | −39.3% | −27.3% | −42.8% | −20.9% | −3.6% | 1.4% |
Debt / equity, FY2016 to FY2025
Total debt / shareholders' equity at the year end.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SUPN Dec | - | - | - | - | - | 0.46 | - | - | - | - |
| AXSM Dec | 0.45 | 0.59 | 7.37 | 0.11 | 0.42 | 3.14 | 0.86 | 0.93 | 3.17 | 2.13 |
| IRTC Dec | 0.50 | 0.56 | 0.67 | 0.26 | 0.10 | 0.08 | 0.15 | 0.17 | - | - |
| INSP Dec | - | 12.40 | 0.15 | 0.18 | 0.11 | 0.11 | 0.00 | - | - | - |
| TGTX Dec | 0.00 | 0.00 | 0.00 | 0.75 | 0.06 | 0.29 | 1.21 | 0.63 | 1.10 | 0.38 |
| RGEN Dec | - | - | - | - | - | - | - | - | 0.27 | 0.26 |
| WRBY Dec | - | - | - | - | - | - | - | - | - | - |
| BBIO Dec | - | - | 0.17 | 0.23 | 1.62 | n/m | n/m | n/m | n/m | n/m |
| IONS Dec | - | - | - | 0.54 | 1.13 | - | 2.08 | 3.38 | 2.13 | 3.71 |
| BCRX Dec | 14.58 | 0.27 | 0.61 | 1.31 | n/m | n/m | n/m | n/m | n/m | n/m |
| Peer median | 0.47 | 0.56 | 0.39 | 0.26 | 0.27 | 0.20 | 0.86 | 0.78 | 1.61 | 1.25 |
EPS (diluted), FY2016 to FY2025
Diluted earnings per share, on today's share count after splits.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SUPN Dec | $1.76 | $1.08 | $2.05 | $2.10 | $2.36 | $0.98 | $1.04 | $0.02 | $1.32 | −$0.68 |
| AXSM Dec | −$1.42 | −$1.27 | −$1.15 | −$2.01 | −$2.77 | −$3.47 | −$4.60 | −$5.27 | −$5.99 | −$3.68 |
| IRTC Dec | −$3.95 | −$1.31 | −$2.11 | −$2.16 | −$1.58 | −$3.46 | −$3.88 | −$4.04 | −$3.63 | −$1.39 |
| INSP Dec | −$16.90 | −$14.88 | −$1.50 | −$1.40 | −$2.19 | −$1.54 | −$1.60 | −$0.72 | $1.75 | $4.89 |
| TGTX Dec | −$1.60 | −$1.91 | −$2.30 | −$1.96 | −$2.42 | −$2.63 | −$1.65 | $0.09 | $0.15 | $2.77 |
| RGEN Dec | $0.34 | $0.72 | $0.37 | $0.44 | $1.11 | $2.24 | $3.24 | $0.63 | −$0.46 | $0.86 |
| WRBY Dec | - | - | - | −$1.10 | −$1.05 | −$2.21 | −$0.96 | −$0.54 | −$0.17 | $0.01 |
| BBIO Dec | - | −$1.00 | −$2.12 | −$2.48 | −$3.80 | −$3.90 | −$3.26 | −$3.95 | −$2.88 | −$3.78 |
| IONS Dec | −$0.50 | $0.15 | $2.07 | $1.90 | −$3.18 | −$0.20 | −$1.90 | −$2.56 | −$3.04 | −$2.38 |
| BCRX Dec | −$0.75 | −$0.78 | −$0.98 | −$940.00 | −$1.09 | −$1.03 | −$1.33 | −$1.18 | −$0.43 | $1.21 |
| Peer median | −$1.42 | −$1.14 | −$1.32 | −$1.96 | −$2.19 | −$2.21 | −$1.65 | −$1.18 | −$0.46 | $0.01 |
Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out SUPN and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more
Sources
Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.
Also
Financials: SUPN's own statements, year by year. Compare: the whole peer group on one page.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SUPN/export.csv") into a cell.